1384984-18-2

Basic information

• Product Name: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea
• Synonyms: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea;VXC-486;EOS-60709;1-ethyl-3-[5-fluoro-6-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-4-[(2R)-oxolan-2-yl]-1H-benzimidazol-2-yl]urea
• CAS NO: 1384984-18-2
• Molecular Formula: C₂₁H₂₅FN₆O₃
• Molecular Weight: 428.4600032
• Mol File: 1384984-18-2.mol

Chemical Properties

• Appearance: /
• Density: 1.374±0.06 g/cm3(Predicted)
• PKA: 8.31±0.30(Predicted)
• CAS DataBase Reference: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea(1384984-18-2)
• EPA Substance Registry System: (R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea(1384984-18-2)

Safety Data

• Hazardous Substances Data: 1384984-18-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea is used as a potential pharmaceutical agent for its diverse structure that may allow for targeted interactions with biological systems. The specific application reason would depend on the results of further research and testing to understand its properties and potential therapeutic effects.
Given the complexity of the compound and the lack of specific application details in the provided materials, the exact uses within the pharmaceutical industry are not specified. However, the compound's structural features suggest it could be developed for various therapeutic applications, such as targeting specific receptors or enzymes in the treatment of diseases. Further research would be necessary to explore these possibilities and to determine the safety and efficacy of the compound in medical applications.

Upstream product

• 1384984-27-3 4-bromo-3-fluoro-6-nitro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-17-1 1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea 
• 1384984-28-4 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol 
• 1319255-87-2 2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)propan-2-ol 
• 1384984-22-8 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran 
• 1384984-29-5 2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol 
• 1384984-26-2 N-(4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoro-acetamide 
• 1384984-25-1 4-bromo-3-fluoro-2-(tetrahydrofuran-2-yl)aniline 
• 1384984-24-0 3-fluoro-2-(tetrahydrofuran-2-yl)aniline 
• 59255-94-6 2-bromo-3-fluoronitrobenzene 

Downstream Products

• 1384984-30-8 (R)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate 

Relevant articles and documents

Second-generation antibacterial benzimidazole ureas: Discovery of a preclinical candidate with reduced metabolic liability

Compound 3 is a potent aminobenzimidazole urea with broad-spectrum Gram-positive antibacterial activity resulting from dual inhibition of bacterial gyrase (GyrB) and topoisomerase IV (ParE), and it demonstrates efficacy in rodent models of bacterial infec

COMBINATION THERAPY COMPRISING|1 -ETHYL-3-[5-[2-{1 -HYDROXY-1 -METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRA HYDROFURAN-2-|YL}-1 H-BENZIMIDAZOL-2-YL]UREA AND DERIVATIVES THEREOF TO TREAT MYCOBACTERIUM|DISEASES

The present invention relates to combination therapies comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhi

SOLID FORMS OF (R)-2-(5-(2-(3-ETHYLUREIDO)-6-FLUORO-7-(TETRAHYDROFURAN-2-YL)-1H-BENZO[D]IMIDAZOL-5-YL)PYRIMIDIN-2-YL)PROPAN-2-YL DIHYDROGEN PHOSPHATE AND SALTS THEREOF

The invention relates to solid forms of the Formula (I) wherein X is -PO(OH)2, -PO(OH)O-M+, or -PO(O-)2?2M+,wherein M is a monovalent cation such as Na+, K+, Li+, or NH4+. The invention also provides pharmaceutically acceptable compositions comprising the solid form of he compound and method of using the compositions in the treatment of various disorders.

GYRASE AND TOPOISOMERASE IV INHIBITORS

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS

The present application is directed to compounds, intermediates and methods for preparing compounds of formula (I) or a pharmaceutically acceptable salts thereof, wherein R is H or F, and each of R3, R4, and R5 are as defined herein. The compounds of formula (I) and pharmaceutical compositions comprising said compounds and salts inhibit bacterial gyrase and/or Topo IV and are useful in treating bacterial infections.

SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA

The present application is directed to solid forms of compounds of formula I: and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.

PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS

The present invention relates to phosphate esters of compounds that inhibit bacterial gyrase and/or Topoisomerase IV and pharmaceutical compositions thereof. These phosphate esters are useful for treating bacterial infections.